本季度信息
截至2025年12月31日止年度，Top Eminent Healthcare Group Limited从上一财年的股东应占综合溢利11,300,000港元转为股东应占综合亏损7,100,000港元。公告显示，B2C销售渠道与数码营销方案的快速拓展推升行政及经营支出，同时因特定企业交易与持续诉讼事项产生了较高的专业及法律费用。此外，其他收入从上一财年的16,300,000港元下降至4,600,000港元，主要由于外汇收益及利息收入减少，整体盈利水平受到明显冲击。
业务分项
公告披露，保健业务持续拓展，并在企业对消费者（B2C）渠道实现增长。随着数字化营销规模扩大，广告投放、客户获取等相关运营费用上升，对盈利造成一定压力。管理层计划加强成本管控和供应链效率，优化产品组合，以应对市场竞争并持续增强B2C业务动能。
展望方面，董事会仍对复苏与长远发展前景保持信心。预计随着战略合作与新产品开发陆续推进，且非经常性成本逐步回归正常水平，未来财务表现有望逐步改善。
高管解读
（本期公告未包含具体高管原话）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.